Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The clomethiazole acute stroke study in ischemic, hemorrhagic, and t-PA treated stroke: Design of a phase III trial in the united states and canada.

Lyden PD, Ashwood T, Claesson L, Odergren T, Friday GH, Martin-Munley S.

J Stroke Cerebrovasc Dis. 1998 Nov-Dec;7(6):435-41.

PMID:
17895123
2.

Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.

Jönsson S, Cheng YF, Edenius C, Lees KR, Odergren T, Karlsson MO.

Clin Pharmacokinet. 2005;44(8):863-78.

PMID:
16029070
3.

Early impairment in consciousness predicts mortality after hemispheric ischemic stroke.

Cucchiara BL, Kasner SE, Wolk DA, Lyden PD, Knappertz VA, Ashwood T, Odergren T, Nordlund A; CLASS-I Investigators.

Crit Care Med. 2004 Jan;32(1):241-5.

PMID:
14707586
4.

Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059.

Green AR, Ashwood T, Odergren T, Jackson DM.

Pharmacol Ther. 2003 Dec;100(3):195-214. Review.

PMID:
14652110
5.

Animal models of stroke: do they have value for discovering neuroprotective agents?

Richard Green A, Odergren T, Ashwood T.

Trends Pharmacol Sci. 2003 Aug;24(8):402-8. Review.

PMID:
12915049
6.

Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients.

Zingmark PH, Ekblom M, Odergren T, Ashwood T, Lyden P, Karlsson MO, Jonsson EN.

Br J Clin Pharmacol. 2003 Aug;56(2):173-83.

7.

Lack of hemispheric dominance for consciousness in acute ischaemic stroke.

Cucchiara B, Kasner SE, Wolk DA, Lyden PD, Knappertz VA, Ashwood T, Odergren T, Nordlund A.

J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):889-92.

8.

Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole.

Centerholt C, Ekblom M, Odergren T, Borgå O, Popescu G, Molz KH, Couturier A, Weil A.

Eur J Clin Pharmacol. 2003 Jun;59(2):117-22. Epub 2003 May 7.

PMID:
12734608
9.

Tolerability of NXY-059 at higher target concentrations in patients with acute stroke.

Lees KR, Barer D, Ford GA, Hacke W, Kostulas V, Sharma AK, Odergren T; SA-NXY-0004 Investigators.

Stroke. 2003 Feb;34(2):482-7.

PMID:
12574564
10.

Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.

Strid S, Borgå O, Edenius C, Jostell KG, Odergren T, Weil A.

Eur J Clin Pharmacol. 2002 Sep;58(6):409-15. Epub 2002 Aug 10.

PMID:
12242600
11.

Somatosensory testing in idiopathic scoliosis.

Olafsson Y, Odergren T, Persson HE, Saraste H.

Dev Med Child Neurol. 2002 Feb;44(2):130-2.

12.

Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results.

Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claesson L, Odergren T, Salazar-Grueso E; CLASS-I/H/T Investigators.

Stroke. 2002 Jan;33(1):122-8.

PMID:
11779900
13.

The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results.

Lyden P, Jacoby M, Schim J, Albers G, Mazzeo P, Ashwood T, Nordlund A, Odergren T.

Neurology. 2001 Oct 9;57(7):1199-205.

PMID:
11591835
14.

Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke.

Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng YF, Odergren T.

Stroke. 2001 Mar;32(3):675-80.

PMID:
11239186
15.

Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus.

Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J.

Diabet Med. 2000 Mar;17(3):181-9.

PMID:
10784221
16.

Cerebral and cerebellar activation in correlation to the action-induced dystonia in writer's cramp.

Odergren T, Stone-Elander S, Ingvar M.

Mov Disord. 1998 May;13(3):497-508.

PMID:
9613744
17.

A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia.

Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H.

J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):6-12.

18.

Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia.

Ansved T, Odergren T, Borg K.

Neurology. 1997 May;48(5):1440-2.

PMID:
9153487
19.

Sternocleidomastoid muscle responses to transcranial magnetic stimulation in patients with cervical dystonia.

Odergren T, Rimpiläinen I, Borg J.

Electroencephalogr Clin Neurophysiol. 1997 Feb;105(1):44-52.

PMID:
9118838
20.

C-peptide improves autonomic nerve function in IDDM patients.

Johansson BL, Borg K, Fernqvist-Forbes E, Odergren T, Remahl S, Wahren J.

Diabetologia. 1996 Jun;39(6):687-95.

PMID:
8781764
21.

[Botulinum toxin--from threat to cure].

Odergren T, Lennerstrand G, Lindestad PA, Hertegård S, Borg J.

Lakartidningen. 1996 Apr 24;93(17):1619-24. Review. Swedish. No abstract available.

PMID:
8667769
22.

Botulinum toxin-induced myopathy in the rat.

Odergren T.

Brain. 1996 Apr;119 ( Pt 2):675-6. No abstract available.

PMID:
8800956
23.

Impaired sensory-motor integration during grasping in writer's cramp.

Odergren T, Iwasaki N, Borg J, Forssberg H.

Brain. 1996 Apr;119 ( Pt 2):569-83.

PMID:
8800949
24.

Activation and suppression of the sternocleidomastoid muscle induced by transcranial magnetic stimulation.

Odergren T, Rimpiläinen I.

Electroencephalogr Clin Neurophysiol. 1996 Apr;101(2):175-80.

PMID:
8647022
25.

Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation.

Odergren T, Tollbäck A, Borg J.

Scand J Rehabil Med. 1994 Dec;26(4):191-5.

PMID:
7878393
26.

Electromyographic single motor unit potentials after repeated botulinum toxin treatments in cervical dystonia.

Odergren T, Tollbäck A, Borg J.

Electroencephalogr Clin Neurophysiol. 1994 Oct;93(5):325-9.

PMID:
7525239

Supplemental Content

Loading ...
Support Center